Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Tanya C. Watt, Todd Cooper

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

Original languageEnglish (US)
Pages (from-to)756-757
Number of pages2
JournalPediatric Blood and Cancer
Issue number4
StatePublished - Oct 2012


  • AML
  • Pediatrics
  • Relapse
  • Sorafenib

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this